Trigeminal Neuralgia (TN), also known as tic douloureux, is a chronic pain condition characterized by severe, sudden, shock-like episodes of facial pain. It is widely regarded as one of the most painful conditions known. The pain is unilateral and strictly confined to the distribution of one or more branches of the fifth cranial (trigeminal) nerve. The attacks are often triggered by innocuous stimuli, leading to significant functional impairment and a drastic reduction in quality of life. A thorough understanding of its clinical features and the stepwise approach to treatment is critical for effective management.

Licensed by Google

Pathophysiology

The underlying cause of classic Trigeminal Neuralgia is, in the vast majority of cases, neurovascular compression at the trigeminal nerve root entry zone into the pons.

• Neurovascular Compression: An aberrant or ectatic blood vessel, most commonly the superior cerebellar artery, is thought to pulsate against the nerve root. This constant pulsation is believed to cause focal demyelination of the nerve, leading to ectopic nerve impulses and the characteristic paroxysmal, high-frequency discharges that manifest as lancinating pain.
• Secondary Trigeminal Neuralgia: In a smaller percentage of cases, TN symptoms are caused by an underlying neurological disease or structural lesion that damages the nerve. The most common secondary cause is Multiple Sclerosis (MS), where a demyelinating plaque affects the trigeminal nerve pathway. Other causes include tumors (e.g., acoustic neuroma, meningioma), cysts, or other vascular malformations.

Clinical Presentation and Diagnosis

The diagnosis of TN is primarily clinical, based on a characteristic history. The International Classification of Headache Disorders (ICHD-3) criteria are highly specific.

Key Features:

1. Pain Quality: Paroxysmal, lasting from a fraction of a second to two minutes. The pain is severe in intensity and often described as “electrical,” “stabbing,” or “shock-like.”
2. Location: Strictly unilateral and follows the distribution of the trigeminal nerve branches. The second (V2 – maxillary) and third (V3 – mandibular) divisions are most commonly affected, either alone or in combination. V1 (ophthalmic) involvement is rare.
3. Triggers: The pain is provoked by light, non-painful stimuli within the affected nerve distribution. Common triggers include:
   • Touching the face (washing, shaving, applying makeup)
   • Chewing or talking
   • Brushing teeth
   • A cool breeze
4. Refractory Period: After an attack, there is typically a refractory period during which a new attack cannot be triggered.
5. Neurological Exam: In classic TN, the neurological examination is typically normal. The presence of sensory deficits (e.g., facial numbness) should raise suspicion for a secondary cause.

Diagnostic Workup:

While the diagnosis is clinical, an MRI of the brain with and without contrast is mandatory in all patients to rule out secondary causes like MS or tumors. High-resolution sequences (e.g., FIESTA, CISS) are particularly useful for visualizing the trigeminal nerve and identifying potential neurovascular compression.

Management

Treatment follows a stepwise approach, starting with pharmacotherapy and escalating to interventional or surgical procedures for refractory cases.

1. First-Line Pharmacotherapy

The anticonvulsants carbamazepine and oxcarbazepine are the only FDA-approved medications and the undisputed first-line treatments for TN.

• Mechanism: They are voltage-gated sodium channel blockers, which stabilizes hyperexcitable neuronal membranes and suppresses the ectopic firing of the trigeminal nerve.
• Dosing: Start low and titrate up slowly to effect.
• Side Effects: Common side effects include drowsiness, dizziness, and ataxia. A serious risk with carbamazepine is the potential for Stevens-Johnson syndrome (SJS), particularly in patients of Asian descent with the HLA-B*1502 allele. Both drugs can also cause hyponatremia.

2. Second-Line Pharmacotherapy

If carbamazepine/oxcarbazepine are ineffective or not tolerated, other agents may be tried, although the evidence is less robust. These include baclofen, lamotrigine, gabapentin, and pregabalin.

3. Surgical and Interventional Management

For patients with medically refractory TN, several procedural options are available.

• Microvascular Decompression (MVD): This is considered the most definitive treatment. It is an open neurosurgical procedure (craniotomy) where the compressing blood vessel is identified and separated from the trigeminal nerve root with a small Teflon sponge. It offers the highest rate of long-term pain freedom but also carries the risks of major neurosurgery.
• Ablative Procedures: These procedures aim to intentionally damage the trigeminal nerve/ganglion to interrupt pain signals. They are less invasive than MVD but tend to have higher recurrence rates and a risk of causing facial numbness (anesthesia dolorosa).
  • Stereotactic Radiosurgery (e.g., Gamma Knife): A non-invasive procedure that delivers a highly focused dose of radiation to the trigeminal nerve root. Pain relief is delayed, often taking several weeks to months.
  • Percutaneous Rhizotomy: These are needle-based procedures performed under fluoroscopic guidance, where a needle is advanced through the foramen ovale to access the Gasserian (trigeminal) ganglion.
    • Glycerol Rhizotomy: Chemical ablation with glycerol.
    • Balloon Compression: Mechanical compression of the ganglion.
    • Radiofrequency Thermocoagulation: Controlled thermal lesioning of the nerve fibers.

Conclusion

Trigeminal Neuralgia is a debilitating condition defined by a classic clinical presentation. Diagnosis is based on history, but an MRI is essential to rule out secondary pathology. The management pathway is well-defined, beginning with sodium channel-blocking anticonvulsants. For patients who fail or cannot tolerate medical therapy, a range of effective surgical and interventional options, from definitive microvascular decompression to less invasive ablative techniques, can provide significant and lasting relief.